In-hospital mortality among resuscitated out-of-hospital cardiac arrest (OHCA) patients remains high. Identifying patients who will benefit from intensive care while avoiding prolonged, potentially unnecessary treatments is essential. Blood-based biomarkers provide a novel method for evaluating brain injury. The abil...
Mikael Laaksonen, Jussi P. Posti, Carita C. Hollmén et al.· Brain Communications· 0 citations
Alzheimer’s disease (AD) develops silently for years before symptoms emerge, making early identification of at-risk individuals essential for prevention trials and early intervention. We tested whether combining neurophysiological, imaging, and blood biomarkers improves prediction of progression to mild cognitive impai...
Jonathan Gallego-Rudolf, A. I. Wiesman, Y. Yakoub et al.· Science Advances· 0 citations
Many AD pQTLs in CSF were enriched in neuroimmune activation, suggesting a genetic basis for neuroimmune dysregulation in AD, and how genetic variation shapes protein expression in the central nervous system is highlighted.
L. Reus, Chen-Yang Jiang, N. Vilor-Tejedor et al.· Molecular Neurodegeneration...· 0 citations
Examination of blood-based T-cell profiles across a range of neurodegenerative dementias provides evidence that T-cell dysregulation is not unified in patients with neurodegenerative diseases and observes different involvement across different dementia types establishing adaptive immunity as a key contributor to diseas...
Frederika Malichova, P. Swann, S. Kigar et al.· Alzheimer's Research & Thera...· 0 citations
CSF p-tau205 as a biomarker of Alzheimer's disease pathology and progression with potential value for biological staging is supported and when incorporated into a conceptual CSF-based staging model, the final p-tau205-positive stage showed the strongest association with cortical atrophy, cognitive impairment, and risk...
J. Lantero-Rodríguez, S. Janelidze, S. Palmqvist et al.· Molecular Psychiatry· 0 citations
Plasma p-tau217 and p-tau181 are effective biomarkers for distinguishing biologically defined EOAD from EOFTD and adding NfL, GFAP, and APOE ε4 status further improves the discriminative accuracy for differentiating EOAD from EOFTD.
H. S. Kwon, So Young Moon, Mina Hwang et al.· Journal of Neurology· 0 citations
This study provides Class II evidence that plasma NfL/p-tau217 discriminates patients with CJD from those with AD and Diagnosing AD with a single abnormal p-tau plasma biomarker risks misdiagnosing prion diseases as AD.
Thomas Coysh, Rhiannon Laban, Elena Veleva et al.· Neurology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
